| Metabolic effects of muraglitazar in type 2 diabetic subjects. | |
| | |
MedLine Citation:
|
PMID: 21615671 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: To assess the effect of muraglitazar, a dual peroxisome proliferator-activated receptor (PPAR)γ-α agonist, versus placebo on metabolic parameters and body composition in subjects with type 2 diabetes mellitus (T2DM). METHODS: Twenty-seven T2DM subjects received oral glucose tolerance test (OGTT), euglycaemic insulin clamp with deuterated glucose, measurement of total body fat (DEXA), quantitation of muscle/liver (MRS) and abdominal subcutaneous and visceral (MRI) fat, and then were randomized to receive, in addition to diet, muraglitazar (MURA), 5 mg/day, or placebo (PLAC) for 4 months. RESULTS: HbA1c(c) decreased similarly (2.1%) during both MURA and PLAC treatments despite significant weight gain with MURA (+2.5 kg) and weight loss with PLAC (-0.7 kg). Plasma triglyceride, LDL cholesterol, free fatty acid (FFA), hsCRP levels all decreased with MURA while plasma adiponectin and HDL cholesterol increased (p < 0.05-0.001). Total body (muscle), hepatic and adipose tissue sensitivity to insulin and β cell function all improved with MURA (p < 0.05-0.01). Intramyocellular, hepatic and abdominal visceral fat content decreased, while total body and subcutaneous abdominal fat increased with MURA (p < 0.05-0.01). CONCLUSIONS: Muraglitazar (i) improves glycaemic control by enhancing insulin sensitivity and β cell function in T2DM subjects, (ii) improves multiple cardiovascular risk factors, (iii) reduces muscle, visceral and hepatic fat content in T2DM subjects. Despite similar reduction in A1c with PLAC/diet, insulin sensitivity and β cell function did not improve significantly. |
| | |
Authors:
|
M Fernandez; A Gastaldelli; C Triplitt; J Hardies; A Casolaro; R Petz; P Tantiwong; N Musi; E Cersosimo; E Ferrannini; R A DeFronzo |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Diabetes, obesity & metabolism Volume: 13 ISSN: 1463-1326 ISO Abbreviation: Diabetes Obes Metab Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-09-07 Completed Date: 2011-12-07 Revised Date: 2012-02-06 |
Medline Journal Info:
|
Nlm Unique ID: 100883645 Medline TA: Diabetes Obes Metab Country: England |
Other Details:
|
Languages: eng Pagination: 893-902 Citation Subset: IM |
Copyright Information:
|
© 2011 Blackwell Publishing Ltd. |
Affiliation:
|
University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, TX 78229-3900, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Body Mass Index Diabetes Mellitus, Type 2 / drug therapy*, metabolism Female Glucose Clamp Technique Glucose Tolerance Test Glycine / administration & dosage, analogs & derivatives*, pharmacology Hemoglobin A, Glycosylated / drug effects*, metabolism Humans Hypoglycemic Agents / administration & dosage, pharmacology* Insulin Resistance Insulin-Secreting Cells / drug effects*, metabolism Intra-Abdominal Fat / drug effects*, metabolism Male Middle Aged Oxazoles / administration & dosage, pharmacology* Peroxisome Proliferator-Activated Receptors / agonists*, metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Oxazoles; 0/Peroxisome Proliferator-Activated Receptors; 0/muraglitazar; 56-40-6/Glycine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal me...
Next Document: Management of urolithiasis in patients after urinary diversions.